SION
NASDAQSionna Therapeutics Inc.
News25/Ratings8
News · 26 weeks680%
2025-10-262026-04-19
Mix1890d
- Insider8(44%)
- Other5(28%)
- SEC Filings4(22%)
- Analyst1(6%)
Latest news
25 items- INSIDERSEC Form 4 filed by Thompson Peter A.4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Orbimed Advisors Llc4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Sionna Therapeutics Inc.SCHEDULE 13D/A - Sionna Therapeutics, Inc. (0002036042) (Subject)
- INSIDERSEC Form 4 filed by Thompson Peter A.4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Orbimed Advisors Llc4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- PRSionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation SymposiumWALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in one-on-one investor meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14th, 2026. About Sionna Therapeutics Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF)
- INSIDERChief Legal Officer Fitzpatrick Jennifer exercised 10,250 shares at a strike of $6.11 and sold $347,019 worth of shares (10,250 units at $33.86) (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- SECSEC Form S-8 filed by Sionna Therapeutics Inc.S-8 - Sionna Therapeutics, Inc. (0002036042) (Filer)
- SECSEC Form S-3ASR filed by Sionna Therapeutics Inc.S-3ASR - Sionna Therapeutics, Inc. (0002036042) (Filer)
- SECSEC Form 10-K filed by Sionna Therapeutics Inc.10-K - Sionna Therapeutics, Inc. (0002036042) (Filer)
- SECSionna Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Sionna Therapeutics, Inc. (0002036042) (Filer)
- PRSionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsOngoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026 Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is on track with topline data anticipated in mid-2026 Maintained strong cash position with approximately $310.3 million in cash and cash equivalents, expected to fund operations into 2028 WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission
- ANALYSTCitizens initiated coverage on Sionna Therapeutics with a new price targetCitizens initiated coverage of Sionna Therapeutics with a rating of Mkt Outperform and set a new price target of $63.00
- PRSionna Therapeutics to Participate in Upcoming March 2026 Investor ConferencesWALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will participate in fireside chats at the following upcoming investor events: TD Cowen 46th Annual Health Care Conference on Monday, March 2nd, 2026, at 2:30 p.m. ET; andLeerink Partners Global Healthcare Conference 2026 on Tuesday, March 10th, 2026, at 1:40 p.m. ET Live webcasts of the presentations can be ac
- INSIDERDirector Thompson Peter A. sold $1,379,866 worth of shares (30,953 units at $44.58) (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERDirector Orbimed Advisors Llc sold $1,379,866 worth of shares (30,953 units at $44.58) (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- PRSionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11th, 2026 at 2:00 p.m. ET. A live webcast of the presentation will be available under the "Events" page within the Investors section of Sionna's website at https://investors.sionnatx.com/. A replay will also
- INSIDERLarge owner Tpg Gp A, Llc sold $10,000,000 worth of shares (250,000 units at $40.00) (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Mckee Charlotte4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer Fitzpatrick Jennifer4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Cloonan Michael4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by Chief Business Officer Beer Caroline Stark4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- INSIDERSEC Form 4 filed by CFO Ridloff Elena4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)
- PRSionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceWALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (NASDAQ:SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026 at 9:45 a.m. PT/12:45 p.m. ET. A live webcast of the presentation will be available under the "Events" page within the Investors section of Sionna's website at https://investors.sionnatx.com/. A replay will also be
- INSIDERDirector Orbimed Advisors Llc sold $1,486,010 worth of shares (33,356 units at $44.55) (SEC Form 4)4 - Sionna Therapeutics, Inc. (0002036042) (Issuer)